Psychotic Disorders: market data & analysis

This market report on Psychotic disorders provides detailed insights into the Psychotic disorders market from a global perspective. Besides all relevant market figures like worldwide revenues from 2016 to 2028, we have deep-dived into regional and country comparisons with a focus on Europe and the Americas.

The Psychotic disorders market was valued at 7.07 billion USD in 2022 and is expected to grow steadily between 2022 and 2028. There has been a significant rise in stress levels among the global population over the last couple of years. This has led to an increase in the incidence of diagnosed psychotic disorders such as schizophrenia and bipolar disorder. The growing prevalence of lifestyle-related mental health conditions, together with the increasing number of diagnosed bipolar disorders, is urging the expansion of efficient treatment options for psychotic disorders. The annual increase in the number of patients suffering from severe mental health disorders has placed a heavy strain on the pharmaceutical industry as well as healthcare services and providers. The largest markets include developed countries including the US, China, Japan, and Canada.

The major players include Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, & Company among others.

Overview

• Summary
• Market Definition
• Key Takeaways

• Revenue
• Average Revenue per Patient
• Patients
• Brand share

• Product Overview
• Author

Market numbers

• Revenue forecast in billion US$
• Average revenue per patient forecast in US$
• Patients forecast in millions
• Brand share in 2022